| NCT ID | NCT06903208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Lipoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-04-02 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-04-02 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lipomas are non-cancerous growths of fatty tissue that develop under the skin in approximately 1 in 1000 people, though this number may be higher. While rarely symptomatic, they often cause emotional distress due to the unappealing appearance of the mass. Treatment of unsightly lipomas is excision with local anesthetic in the office or with sedation in the operating room. The recovery period is short and the procedure is low risk; however, the result of the operation is a visible scar over the site of the lipoma. Many patients defer surgical excision because excision of a lipoma is a cosmetic procedure, but the aesthetic outcome is undesirable. Radiofrequency ablation (RFA) is a technique that applies heat generated by a high frequency, alternating current to soft tissue. The hyperthermia produced by the current causes tissue necrosis that ablates the tissue into which the energy is directed. RFA has been successfully applied to thyroid nodules, pancreatic lesions, esophageal dysplasia and liver tumors. However, the manufacturers of the RFA technology have been focused on its application in pre-malignant and malignant lesions and have not yet considered its application to benign tumors. This study will test the success of RFA for superficial lipomas as a non-surgical option for treatment.
Eligibility Criteria
Inclusion Criteria: * Patients \>18 years old * Patients with a lipoma \<5 cm, above the fascia on the trunk, abdomen or extremities Exclusion Criteria: * Lipomas of the face or neck * Angiolipomas (identified on exam as a firm, mobile, occasionally discolored mass) * Patients with history of hereditary retinoblastoma, Li-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis, tuberous sclerosis and Werner syndrome * A history of exposure to herbicides, arsenic and dioxin * A history of radiation treatment for other cancers
Contact & Investigator
Katherine Fischkoff, MD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT06903208 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lipoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06903208 currently recruiting?
Yes, NCT06903208 is actively recruiting participants. Visit ClinicalTrials.gov or contact Columbia University to inquire about joining.
Where is the NCT06903208 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06903208 clinical trial?
NCT06903208 is sponsored by Columbia University. The principal investigator is Katherine Fischkoff, MD at Columbia University. The trial plans to enroll 10 participants.